PHARMACOGENETICS OF ACE INHIBITOR-ASSOCIATED ANGIOEDEMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目的1.通过研究BK和P物质受体拮抗剂对血管紧张素转换酶抑制剂相关血管水肿的持续时间和严重程度的影响，验证BK或P物质通过APP/DPPIV途径的异常降解导致血管紧张素转换酶抑制剂相关性血管水肿的假说。 具体目的2.根据BK和P物质降解表型鉴定血管紧张素转换酶抑制剂相关性血管性水肿家系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific Aim 1. To test the hypothesis that aberrant degradation of either BK or substance P through the APP/DPPIV pathway contributes to ACE inhibitor-associated angioedema in humans, by investigating the effect of BK and substance P receptor antagonism on the duration and severity of ACE inhibitor-associated angioedema. Specific Aim 2. To identify and characterize kindreds with ACE inhibitor-associated angioedema according to BK and substance P degradation phenotype.